Next Article in Journal
Associations of Plasma Concentration Profiles of Dapagliflozin, a Selective Inhibitor of Sodium–Glucose Co-Transporter Type 2, with Its Effects in Japanese Patients with Type 2 Diabetes Mellitus
Previous Article in Journal
Efficacy, Safety and Patient-Reported Outcomes with Preservative-Free (PF) Tafluprost or PF-Dorzolamide/Timolol Compared with Preserved Latanoprost: A Prospective Multicenter Study in Korean Glaucoma Patients with Ocular Surface Disease
 
 
Article

Article Versions Notes

Pharmaceuticals 2022, 15(2), 204; https://doi.org/10.3390/ph15020204
Action Date Notes Link
article pdf uploaded. 7 February 2022 13:33 CET Version of Record https://www.mdpi.com/1424-8247/15/2/204/pdf-vor
article supplementary file uploaded. 7 February 2022 13:33 CET - https://www.mdpi.com/1424-8247/15/2/204#supplementary
article xml file uploaded 10 February 2022 05:13 CET Original file -
article xml uploaded. 10 February 2022 05:13 CET Update -
article pdf uploaded. 10 February 2022 05:13 CET Updated version of record https://www.mdpi.com/1424-8247/15/2/204/pdf
article html file updated 10 February 2022 05:14 CET Original file -
article xml file uploaded 22 February 2022 05:46 CET Update -
article xml uploaded. 22 February 2022 05:46 CET Update https://www.mdpi.com/1424-8247/15/2/204/xml
article html file updated 22 February 2022 05:48 CET Update -
article html file updated 31 July 2022 11:42 CEST Update https://www.mdpi.com/1424-8247/15/2/204/html
Back to TopTop